Login to Your Account



Clinic Roundup


Wednesday, February 20, 2013
• C3 Jian Inc., of Los Angeles, said it completed enrollment in a Phase I study testing C16G2, a synthetic peptide derived from its pheromone signaling platform technology called STAMPS (Specifically Targeted Antimicrobial Peptides).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription